Skip to main content
Premium Trial:

Request an Annual Quote

NCCN Recommends Testing for KRAS Mutation Before Treating Colorectal Cancer

NEW YORK (GenomeWeb News) – The National Comprehensive Cancer Network has updated its guidelines to recommend that oncologists determine the KRAS gene status of either a primary tumor or a metastasizing site as part of pre-treatment work-up for patients diagnosed with colon cancer.
 
The NCCN, a non-profit organization comprising 21 cancer centers, also recommended that only those patients with tumors characterized by the wild-type KRAS gene be treated with certain epidermal growth factor receptor inhibitor drugs including Bristol-Myers Squibb’s Erbitux and Amgen's Vectibix.
 
NCNN said that the recommendations in its updated Colon and Rectal Cancer Guidelines were in response to “a number of recent studies” showing that the KRAS gene status can help predict the outcome of anti-EGFR therapies.
 
For example, at the annual American Society of Clinical Oncology conference in June, researchers from the University Hospital Gasthuisberg in Leuven, Belgium, discussed a 587-patient study that found that 59.3 percent of patients with the wild-type KRAS gene responded to treatment with Erbitux and chemotherapy, compared to 43.2 percent of patients who responded to chemotherapy alone.
 
Diagnostic tests for KRAS status are currently made by DxS, TrimGen, Response Genetics, and Caris Diagnostics.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.